Jefferies Financial Group Inc. Purchases 29,860 Shares of Eton Pharmaceuticals, Inc. $ETON

Jefferies Financial Group Inc. raised its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 33.8% in the fourth quarter, HoldingsChannel reports. The firm owned 118,300 shares of the company’s stock after acquiring an additional 29,860 shares during the period. Jefferies Financial Group Inc.’s holdings in Eton Pharmaceuticals were worth $2,000,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ETON. Millennium Management LLC raised its position in Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Eton Pharmaceuticals by 34.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after purchasing an additional 45,341 shares in the last quarter. Jane Street Group LLC raised its position in Eton Pharmaceuticals by 49.1% during the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after purchasing an additional 31,596 shares in the last quarter. JPMorgan Chase & Co. raised its position in Eton Pharmaceuticals by 114.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock valued at $3,457,000 after purchasing an additional 129,467 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $41,000. 27.86% of the stock is owned by institutional investors.

Insider Transactions at Eton Pharmaceuticals

In related news, insider David Krempa sold 42,797 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the transaction, the insider directly owned 25,249 shares of the company’s stock, valued at $843,064.11. This represents a 62.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders sold 100,000 shares of company stock worth $3,229,921. Corporate insiders own 16.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ETON shares. Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. B. Riley Financial upped their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Finally, HC Wainwright raised their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eton Pharmaceuticals has an average rating of “Hold” and a consensus price target of $41.00.

Eton Pharmaceuticals Stock Up 3.5%

NASDAQ:ETON opened at $32.40 on Thursday. Eton Pharmaceuticals, Inc. has a fifty-two week low of $13.09 and a fifty-two week high of $35.66. The stock has a market capitalization of $887.44 million, a P/E ratio of -462.79 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. The company’s 50-day simple moving average is $26.59 and its 200-day simple moving average is $20.03.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. On average, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.